Having psoriasis on your arms can be uncomfortable and embarrassing Medically reviewed by Susan Bard, MD Having psoriasis on the arms, a part of the body that is often visible to others, can be ...

Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

Localized pustular psoriasis is a term that refers to a limited area of small pus-filled blisters on your skin, typically on your hands or feet. It is distinct from generalized pustular psoriasis (GPP ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe form of ...

Please provide your email address to receive an email when new articles are posted on . Biologic therapies demonstrated improved morbidity and mortality outcomes compared with oral agents and steroids ...

A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly more healthcare visits and costs than patients with plaque psoriasis alone. Researchers ...

Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling is involved in the ...

Psoriasis is a chronic skin disease where red, scaly, itchy patches break out all over your body. It’s an autoimmune disease in which your immune system goes haywire and triggers inflammation of your ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...